Navigation Links
Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
Date:10/27/2010

BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company generated revenues during the three months ended September 30, 2010 in the amount of $134,426 versus $99,710 for the three months ended September 30, 2009.  This was an increase of 34.8% for the three months during 2010 as compared to 2009.

Despite a down global economy, Solos has been able to increase its sales transactions due to consistent product orders from the Company's current customer base. Over the past twelve months, Solos has placed an emphasis on promoting and marketing its MammoView® product line to hospitals and cancer centers. Revenue for the third quarter was driven by sales from the MammoView® line as well as strong sales from its standard product line with increased orders for the Company's Vascular Clamp System.

"We completed another strong quarter of sales in 2010," stated Bob Segersten, President of Solos Endoscopy, Inc. "Year-to-date, we have delivered double-digit revenue growth in what continues to be a challenging economic environment."

The Company expects to post its full unaudited financial results for the three months ended September 30, 2010 on the Pink Sheets OTC Markets website within in the next forty-five days.

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line. In addition, Solos plans to achieve market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
2. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
3. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
4. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
5. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
6. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
7. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
8. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
9. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
10. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
11. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):